Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

Drug regulators protect profits over patients, new study finds

May 11, 2011 Research and Development Bad Science, Vioxx, regulatory affairs

Medicine regulators are protecting drug company profits over the welfare of patients by withholding trial data. That’s the verdict of …
News

Verdict on AMT’s gene therapy expected soon

May 11, 2011 Research and Development, Sales and Marketing AMT, Amsterdam Molecular Therapeutics, gene therapy, genes

Amsterdam Molecular Therapeutics says it will shortly receive the regulatory verdict on its gene therapy Glybera. Glybera (alipogene tiparvovec) is …
News

Pfizer drops early-stage asthma candidate

May 11, 2011 Research and Development Pfizer, Rigel, asthma

Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals. San Francisco-based Rigel says Pfizer is …
News

Service Insight: Clinical trials – managing route to market

May 11, 2011 Research and Development Service Insight, Talking Point, research and development

SERVICE INSIGHT Clinical trials are notoriously difficult to manage and often fraught with problems, as they can involve many clinical …
Feature
Sanofi's new logo

Sanofi name change sees Aventis dropped

May 9, 2011 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis

Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …
News

Thomas Lingelbach appointed chief executive of Intercell

May 5, 2011 Research and Development appointment, research and development

Vienna-based biotech Intercell has appointed Thomas Lingelbach as chief executive with effect from 10 May. He has more than twenty …
Appointment

INC Research to acquire Kendle

May 5, 2011 Research and Development INC Research, Kendle, cros

Two contract research organisations INC Research and Kendle International are to merge to create a new major player in the …
News

Sanofi signs malaria research alliance

May 5, 2011 Research and Development Medicines for Malaria Venture, Sanofi-Aventis, malaria

Sanofi-Aventis has signed a research deal with the Medicines for Malaria Venture charity. They will work together to identify, characterise …
News

Debiopharm and Yale University to develop autoimmune treatment

May 5, 2011 Research and Development Debiopharm, Yale University

Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …
News
Roche's Avastin (bevacizumab)

Avastin as effective as Lucentis in eye disease

May 4, 2011 Research and Development Lucentis, avastin, off label, wet AMD

Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …
News

Service Insight: Due diligence in emerging markets for clinical development

May 4, 2011 Research and Development Service Insight, Talking Point, research and development

SERVICE INSIGHT Currently, the pharma industry is experiencing an unprecedented wave of blockbuster drug patent expiries. There is a lack …
Feature

Contract research news in brief

May 4, 2011 Research and Development contract research, cros, research and development

This week’s CRO news roundup includes Omnicare CR and LAB Research changing hands, Q1 financials for ICON and PPD and …
News

Astellas adds senior executives to global development team

May 4, 2011 Research and Development appointment, research and development

Astellas Pharma has made four new senior appointments to its US-based global development team. Former Eli Lilly vice president of …
Appointment
Cephalon

Cephalon accepts Teva’s $6.8 billion white knight bid

May 3, 2011 Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
News
Boehringer Ingelheim

Boehringer begins late-stage hep C trial

April 27, 2011 Research and Development BI 201335, Boehringer Ingelheim, hepatitis C

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026